Creatine, a ubiquitous compound primarily recognized for its role in augmenting athletic performance and fostering muscular development, is now at the center of burgeoning scientific inquiry into its potential therapeutic applications for mental health conditions, specifically depression. A recent comprehensive analysis, meticulously compiled and disseminated in the esteemed journal Brain Medicine, has delved into the existing body of clinical research to ascertain whether this popular dietary supplement could offer a novel avenue for alleviating depressive symptoms by bolstering the brain’s inherent energy reserves. The outcomes of this systematic review, while tinged with a degree of cautious optimism, unequivocally underscore the substantial gaps in our current understanding, revealing a complex and as yet unresolved scientific narrative. While a select number of meticulously designed clinical investigations have reported statistically significant improvements in individuals experiencing depressive episodes, a countervailing set of studies has failed to demonstrate any discernible benefit, leaving the scientific community grappling with a compelling research question rather than a definitive conclusion.
Rather than embarking on the initiation of novel experimental protocols, the research team, spearheaded by Bassam Jeryous Fares, an academic affiliated with the University of Ottawa, undertook a rigorous evaluation of previously published research endeavors. This exhaustive review of the extant literature culminated in the identification of six distinct scholarly reports, which collectively encompassed five randomized controlled trials. Within these trials, participants were administered either creatine or a placebo, a controlled substance devoid of active ingredients, with neither the participants nor the administering researchers aware of the specific treatment allocation, a methodology designed to mitigate observer bias.
The geographical origins of these pivotal studies spanned a diverse international landscape, including South Korea, the United States, Brazil, Israel, and India, reflecting a global scientific effort to probe this intriguing hypothesis. Collectively, these trials initially involved 238 individuals, of whom 126 were assigned to receive creatine supplementation and 112 were allocated to the placebo group. The average age of the participants hovered around 36 years, and a notable demographic characteristic was the significant representation of women, with two of the included studies specifically recruiting exclusively female cohorts. The investigative focus of four of these trials was directed towards individuals diagnosed with major depressive disorder, whereas the remaining study extended its scope to encompass participants grappling with bipolar disorder who were concurrently experiencing a depressive phase. Acknowledging the considerable heterogeneity in the experimental designs and methodological approaches employed across these studies, the researchers opted against aggregating the data into a singular, overarching statistical analysis. Instead, each individual study was subjected to an independent and detailed assessment of its findings.
The findings emerging from this systematic examination painted a decidedly bifurcated and intricate picture regarding creatine’s efficacy in addressing depression. Within the cohort of five evaluated trials, two distinct studies, both of which exclusively involved women diagnosed with major depressive disorder, provided compelling evidence suggesting that creatine supplementation conferred additional therapeutic advantages. In one of these studies, participants who incorporated five grams of creatine daily into their treatment regimen, alongside their prescribed antidepressant medication escitalopram, exhibited a demonstrably greater amelioration of depressive symptoms after an eight-week intervention period when contrasted with a control group receiving escitalopram in conjunction with a placebo. This observed improvement was deemed substantial by conventional statistical metrics, registering a Cohen’s d of 1.13 on the Hamilton Depression Rating Scale, a widely recognized instrument for assessing depressive severity, and a higher proportion of participants in the creatine group achieved clinical remission. In a separate investigation, creatine was administered in conjunction with cognitive behavioral therapy, a form of psychotherapy. Participants who received this combined treatment demonstrated a more pronounced reduction in depression symptoms, as measured by a standardized assessment tool, compared to those who underwent therapy augmented by a placebo.
Conversely, the remaining three trials failed to substantiate any statistically significant or clinically meaningful benefit attributable to creatine supplementation. One particular study reported that neither a daily dose of five nor ten grams of creatine effectively mitigated symptoms in individuals whose depression had proven refractory to conventional pharmacological interventions. Another investigation found no discernible advantage over placebo among adolescent girls, even when various dosages of creatine were administered and evaluated. Furthermore, a third trial, which focused on individuals diagnosed with bipolar disorder and experiencing depressive episodes, also yielded negative results, indicating no observable improvement in their condition. Beyond the efficacy data, the researchers also highlighted a crucial safety consideration. Two participants diagnosed with bipolar disorder who were administered creatine experienced adverse events, specifically the development of hypomania or mania, suggesting that creatine’s physiological effects might be modulated by an individual’s underlying psychiatric condition.
The scientific rationale underpinning the hypothesis that creatine might exert a beneficial influence on depression is deeply rooted in the brain’s exceptionally high and constant energy demands. While creatine is predominantly celebrated for its capacity to facilitate the rapid regeneration of adenosine triphosphate (ATP), the fundamental cellular energy currency, within muscle tissues, the brain also exhibits a profound reliance on this intricate energy metabolic pathway. Prior scientific investigations have identified alterations in brain creatine metabolism among individuals diagnosed with mood disorders, thereby prompting researchers to explore whether dysfunctions in cellular energy production could indeed be a contributing factor to the pathophysiology of depression. Furthermore, there is a theoretical basis suggesting that creatine might modulate the activity of dopamine and serotonin, two key neurotransmitters critically involved in mood regulation and frequently targeted by established antidepressant medications.
Notwithstanding these promising theoretical connections, the authors of the systematic review emphatically caution that these observed relationships remain largely speculative. The existing empirical studies predominantly highlight correlations rather than establishing definitive causal links, and the complex nature of depression itself involves a myriad of intricate biological pathways and mechanisms. Bassam Jeryous Fares, the lead author of the review and a student at the University of Ottawa’s Faculty of Medicine, aptly summarized the current state of evidence, stating, "The signal is interesting, but it is not a verdict." He elaborated, "Two trials pointed one way and three pointed another. That is not the kind of evidence on which you change clinical practice. It is the kind that tells you the question is worth further exploration." Nicholas Fabiano, the corresponding author of the review and a psychiatry resident at the University of Ottawa, echoed this sentiment of caution, advising, "Creatine appears to be a safe intervention. The adverse events we found were limited to mild gastrointestinal discomfort. We cannot yet reliably say that creatine helps with depressive symptoms or if the findings are generalizable to everyone."
The researchers involved in this analysis strongly emphasize that the current body of evidence is significantly insufficient to advocate for the routine utilization of creatine as a therapeutic intervention for depression. The clinical trials that have been conducted thus far are characterized by relatively small sample sizes, a disproportionate representation of women compared to men, and considerable variability in their methodological quality. While two of the included studies were assessed as having a low risk of bias, the remaining three raised certain concerns, primarily pertaining to issues surrounding participant allocation concealment and the handling of missing data. Consequently, the findings derived from these studies cannot be broadly extrapolated or applied to the general population.
In light of these limitations, the review advocates for the initiation of larger-scale, longer-duration clinical trials that extend beyond the typical eight-week intervention periods. The researchers also propose investigating the potential synergistic effects of creatine when administered in conjunction with exercise, a well-established adjunct therapy for depression. Furthermore, they recommend exploring whether varying dosages of creatine might yield differential outcomes, while simultaneously acknowledging that higher doses do not necessarily translate into augmented benefits. Insights from animal studies may also offer valuable clues. Experiments involving rodents have demonstrated that creatine can differentially influence depression-like behaviors in male and female subjects, a finding that could potentially elucidate the stronger positive results observed in human studies that predominantly featured female participants.
For the present moment, creatine represents an intriguing scientific possibility rather than a clinically validated treatment modality for depression. A dietary supplement historically synonymous with the pursuit of enhanced physical prowess is now garnering significant scientific attention from researchers actively seeking novel and effective strategies for addressing the pervasive challenge of depression. The peer-reviewed research article, titled "Creatine as a treatment for depression," was published in Brain Medicine and has been made accessible through Open Access, commencing June 30, 2026.
About the Author
